Mechanism

treatment

comparator

All cause death

Coronary event

Adverse events

Cardiovascular death

Non fatal MI

stroke (fatal and non fatal)

myocardial infarction (fatal and non fatal)

hospitalisation for heart failure

cardiac death

cardiovascular events

CABG

Adverse events leading to treatment discontinuation

CV death, MI hospitalization for HF

Angina episodes per week

Nitroglycerin use per week

Recurrent ischemia

angina frequency

unstable angina

Coronary revascularization

Cardiovascular death or hospital admission for CHF

PCI

Hospitalization for angina

Time to 1 mm ST depression (s)

Time to angina onset (s)

Time to limiting angina (s)

Total exercise duration (s)

Nicorandil

coronary artery disease, in hemodialysis patients

vs control

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	no data
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
Nishimura, 2009	nicorandil 15 mg daily	control	Maintenance hemodialysis patients who underwent percutaneous coronary artery intervention and had complete coronary revascularization (absence of both restenosis and de novo coronary lesion) at coronary arteriography 6 months later

Nicorandil

percutaneous coronary intervention, in hemodialysis patients

vs control

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	no data
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
Nishimura, 2009	nicorandil 15 mg daily	control	Maintenance hemodialysis patients who underwent percutaneous coronary artery intervention and had complete coronary revascularization (absence of both restenosis and de novo coronary lesion) at coronary arteriography 6 months later

Ranolazine

acute coronary syndrome, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.98 [0.79 1.22]	p=1.00	0	6560	1	MERLIN TIMI 36,
Coronary event	no data
Adverse events	no data
Cardiovascular death	0.99 [0.79 1.26]	p=1.00	0	6560	1	MERLIN TIMI 36,
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	0.97 [0.81 1.17]	p=1.00	0	6560	1	MERLIN TIMI 36,
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	0.87 [0.76 1.00]	p=1.00	0	6560	1	MERLIN TIMI 36,
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
MERLIN TIMI 36, 2007	ranolazine 1000 mg twice daily for the duration of the trial (intitialy 200 mg intravenously for 1 hour, followed by an 80 mg/h intravenous infusion)	placebo	Hospitalized with NSTE-ACS; ischemic symptoms at rest within 48 hours; and at least one indicator of moderate to high risk, defined as elevated troponin or creatine kinase-myocardial band, ST-depression >0.1 mV, diabetes, or TIMI risk score for unstable angina/NSTEMI >=3

Ranolazine

coronary artery disease, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	no data
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
MARIZA, 2004	ranolazine 500 mg twice daily (sustained-release ranolazine 500, 1,000, or 1,500 mg)	placebo	Patients with angina-limited exercise
RAN080, 2005	ranolazine IR 400mg TID	placebo	patients who had symptom-limited exercise

Ranolazine

coronary artery disease, in all type of patients

vs placebo (on top standard treatment)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	no data
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
CARISA 1000mg, 2004	ranozaline 1000mg (in combination with beta-blockers or calcium antagonists)	placebo	patients with severe chronic angina who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem

Ranolazine

coronary artery disease, in all type of patients

vs placebo + amlodipine

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	no data
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
ERICA, 2006	ranolazine 1000 mg twice a day for 6 weeks + amlodipine (10 mg/d)	placebo + amlodipine (10 mg/d)	patients with stable chronic angina already treated with the maximal dose of amlodipine (10mg/d)

Ranolazine

stable angina, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	no data
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
MARIZA, 2004	ranolazine 500 mg twice daily (sustained-release ranolazine 500, 1,000, or 1,500 mg)	placebo	Patients with angina-limited exercise
RAN080, 2005	ranolazine IR 400mg TID	placebo	patients who had symptom-limited exercise

Ranolazine

stable angina, in all type of patients

vs placebo (on top standard treatment)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	no data
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
CARISA 1000mg, 2004	ranozaline 1000mg (in combination with beta-blockers or calcium antagonists)	placebo	patients with severe chronic angina who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem

Ranolazine

stable angina, in all type of patients

vs placebo + amlodipine

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
myocardial infarction (fatal and non fatal)	no data
hospitalisation for heart failure	no data
cardiac death	no data
cardiovascular events	no data
CABG	no data
Adverse events leading to treatment discontinuation	no data
CV death, MI hospitalization for HF	no data
Angina episodes per week	no data
Nitroglycerin use per week	no data
Recurrent ischemia	no data
angina frequency	no data
unstable angina	no data
Coronary revascularization	no data
Cardiovascular death or hospital admission for CHF	no data
PCI	no data
Hospitalization for angina	no data
Time to 1 mm ST depression (s)	no data
Time to angina onset (s)	no data
Time to limiting angina (s)	no data
Total exercise duration (s)	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
ERICA, 2006	ranolazine 1000 mg twice a day for 6 weeks + amlodipine (10 mg/d)	placebo + amlodipine (10 mg/d)	patients with stable chronic angina already treated with the maximal dose of amlodipine (10mg/d)

anti-anginal drugs